Linsitinib

Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the IGF-1 receptor and insulin receptor (IR) with IC50s of 35 and 75 nM, respectively[1].

Product Specifications

CAS Number

[867160-71-2]

Product Name Alternative

OSI-906

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

IGF-1R; Insulin Receptor

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Linsitinib.html

Purity

99.87

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O[C@@]1(C)C[C@@H](C2=NC(C3=CC=C4C=CC(C5=CC=CC=C5)=NC4=C3)=C6C(N)=NC=CN62)C1

Molecular Formula

C26H23N5O

Molecular Weight

421.49

Precautions

H302, H315, H319, H335

References & Citations

[1]Mulvihill MJ, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and IR. Future Med Chem. 2009 Sep;1 (6) :1153-71.|[2]McKinley ET, et al. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin Cancer Res. 2011 May 15;17 (10) :3332-40.|[3]Li W, et al. Effectiveness of inhibitor rapamycin, saracatinib, linsitinib and JNJ-38877605 against human prostate cancer cells. Int J Clin Exp Med. 2015 Apr 15;8 (4) :6563-7.